Microsure Founders
Science Park Eindhoven 5080, Son en Breugel, Noord-Brabant, 5692 EA, The Netherlands
Overview
Microsurgery is characterized by performing surgery close to the limits of what is physically possible. It has designed a motion stabilizer system, which is designed by and for microsurgeons who want to overcome their physical limitations and enhance their performance. The Microsure motion stabilizer system has improved the quality of microsurgical procedures and makes it easier to perform, with the objective to increase the number of treatment options for patients. The extraordinary control and precision offered by the Microsure motion stabilizer provides better and more constant surgical outcome and allows the development of new highly accurate surgical procedures that are currently unavailable. The Microsure system has already been successfully used in a first clinical trial with 8 micro-surgical operations for lymphedema in the Maastricht UMC+. With our investment, Microsure will accelerate the market introduction and sales of its systems. Microsure was founded in 2014 and is headquartered in Eindhoven, The Netherlands.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Health Care
- Hospital
- Medical Device
Investment portfolio
- Microsure
Participated · Series B · Oct 2023
Microsure develops robot-assisted systems for microsurgery, notably the MUSA-3 which is designed in close cooperation with microsurgeons and engineers. The company says MUSA-3 provides precision for microsurgeons and enables interventions that are virtually impossible to perform by hand. Microsure intends to use the new funding to finalize MUSA-3 development for clinical studies, followed by FDA clearance in the USA and CE-marking in Europe. The company is led by CEO Sjaak Deckers and was founded in 2016 by Eindhoven University of Technology and Maastricht University Medical Center. Microsure is based in Eindhoven, The Netherlands, and currently employs over 30 technical professionals. The recent financing strengthens its position to complete clinical validation and regulatory approvals. Microsure develops robot-assisted systems for microsurgery; its leading product MUSA is the first CE-marked and clinically available surgical robot assistant for open microsurgery. MUSA scales down motion and filters tremor to provide steadier manipulation, targeting procedures such as lymphatic-venous anastomosis, distal nerve repair and vascularized tissue transplantation. The company closed a €2.7 million Series B extension to continue the initial clinical roll-out and to further develop improvements to the system. The planned broader market availability of the improved MUSA system is expected in the course of 2022 after Covid-19 related delays. Microsure was founded in 2016 and is based in Eindhoven; it works with clinical and technical advisors including Maastricht University Medical Center+ as a leading clinical partner.